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Abstract: Studies have shown that mutations in the matrilin-3 gene (MATN3) are 
associated with multiple epiphyseal dysplasia (MED) and spondyloepimetaphyseal 
dysplasia (SEMD). We tested whether MATN3 mutations affect the differentiation of 
chondroprogenitor and/or mesenchymal stem cells, which are precursors to chondrocytes. 
ATDC5 chondroprogenitors stably expressing wild-type (WT) MATN3 underwent 
spontaneous chondrogenesis. Expression of chondrogenic markers collagen II and 
aggrecan was inhibited in chondroprogenitors carrying the MED or SEMD MATN3 
mutations. Hypertrophic marker collagen X remained attenuated in WT MATN3 
chondroprogenitors, whereas its expression was elevated in chondroprogenitors expressing 
the MED or SEMD mutant MATN3 gene suggesting that these mutations inhibit 
chondrogenesis but promote hypertrophy. TGF-β treatment failed to rescue chondrogenesis 
markers but dramatically increased collagen X mRNA expression in mutant MATN3 
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expressing chondroprogenitors. Synovium derived mesenchymal stem cells harboring the 
SEMD mutation exhibited lower glycosaminoglycan content than those of WT MATN3  
in response to TGF-β. Our results suggest that the properties of progenitor cells  
harboring MATN3 chondrodysplasia mutations were altered, as evidenced by attenuated 
chondrogenesis and premature hypertrophy. TGF-β treatment failed to completely rescue 
chondrogenesis but instead induced hypertrophy in mutant MATN3 chondroprogenitors. 
Our data suggest that chondroprogenitor cells should be considered as a potential target of 
chondrodysplasia therapy.  
Keywords: matrilin-3; multiple epiphyseal dysplasia; spondyloepimetaphyseal dysplasia; 
chondroprogenitor; chondrogenesis; TGF-β 
 
1. Introduction 
Endochondral bone formation is the primary means of skeletal development in vertebrates. During 
this process, growth plate chondrocytes undergo rapid proliferation and differentiation into mature 
chondrocytes. These chondrocytes further differentiated into hypertrophic chondrocytes that, in time, 
ossify as the diaphysis elongates resulting in long bone growth. The crippling effects of 
chondrodysplasia illustrate the importance of cartilage development to the process of normal bone 
growth. Multiple epiphyseal dysplasia (MED) [1] and matrilin type spondyloepimetephyseal dysplasia 
(SEMD, matrilin type) [2] are two forms of chondrodysplasia associated with mutations in the matrilin-3 
(MATN3) gene. MATN3 is a small non-collagenous extracellular matrix (ECM) protein consisting of a 
von Willebrand factor A (vWFA) domain, four consecutive epidermal growth factor (EGF) repeats and 
a single coiled-coil domain [3]. MATN3 is specific to cartilage tissue and highly expressed by growth 
plate chondrocytes during development [3,4]. Despite our current understanding of its molecular 
interaction with other cartilage ECM proteins, such as type II/IX collagens [5,6], cartilage oligomeric 
matrix protein COMP [7] and matrilin-1 (MATN1) [3,8–10], the biological role of MATN3 remains 
largely unknown. 
MED is characterized by delayed or irregular epiphyseal ossification often followed by the early onset 
of osteoarthritis in patients [11–13]. Currently there are more than 13 known MED associated autosomal 
dominant missense mutations have been mapped to MATN3’s vWFA protein domain [14–19]. A single 
tryptophan to arginine (R121W) point mutation in the β-strand of the vWFA domain has been 
identified in approximately one third of all MED patients, making it the most common MATN3 
mutation to cause this disorder [1,17]. Furthermore, an autosomal recessive cysteine to serine (C304S) 
point mutation within the first EGF-like domain of MATN3 has been identified in patients with SEMD [2].  
Studies to analyze the underlying mechanisms of chondrodysplasia have previously focused on the 
effects of the MATN3 missense mutations on chondrocytes. In vitro studies have been conducted using 
primary bovine and chicken chondrocytes, which transiently over-expressed MED (R116W) and 
SEMD (C299S) MATN3 mutations, the murine analogs of the human R121W and C304S MATN3 
mutations, respectively [16,20]. These mutations led to disturbed protein trafficking to the Golgi and 
ultimately resulted in cellular retention of MATN3 in the endoplasmic reticulum of cells. These data 
Int. J. Mol. Sci. 2014, 15 14557 
 
 
suggest that cytosolic accumulation of MATN3 protein may be an underlying pathophysiological event 
responsible for chondrodysplasia [16,20]. Additionally, an in vivo study using knock-in mice carrying 
the murine equivalent of the MED associated MATN3 point mutation (V194D) has shown that this 
mutation results in disregulated chondrocyte proliferation, apoptosis, ER stress response and the 
development of chondrodysplasia [21].  
While these previous studies helped to establish that MATN3 is an important ECM protein in 
regulating cartilage development and homeostasis, they did not address whether chondrodysplasia 
associated MATN3 mutations can also affect chondroprogenitors, a precursor cell population that  
gives rise to chondrocytes. Chondroprogenitors reside in the resting zone, peri-chondrium, growth plate 
groove of Ranvier, articular cartilage and neighboring tissues in the joint (including synovium) [22]. 
Chondroprogenitors, which derive from mesenchymal stem cells, are crucial for proper endochondral 
ossification and bone development through chondrogenesis to form chondrocytes upon induction by 
growth factors such as TGF-β. During this differentiation process, chondrocytes undergo sequential, 
well-coordinated events including proliferation, synthesis of chondrogenic markers such as collagen II 
(Col2a1) and aggrecan (Acan), and eventually, hypertrophy and synthesis of hypertrophic marker 
collagen X (Col10a1). Unlike MATN1, which is expressed mainly by post-mitotic mature 
chondrocytes [23], MATN3 is predominantly expressed during early chondrogenesis in the growth 
plate [10]. Thus, MATN3 mutations may affect not only chondrocytes but also mesenchymal stem cell 
derived chondroprogenitors that harbor such mutations. Alteration of these precursor cells may affect 
the microenvironment of the ECM within the growth plate or articular cartilage and the downstream 
events during chondrocyte differentiation, thereby contributing to the pathogenesis of MED and SEMD.  
To test this hypothesis, we established stable chondroprogenitor cell lines harboring either the  
wild-type (WT), MED or SEMD mutant MATN3 gene in ATDC5 cells, which are commonly 
recognized chondroprogenitor cells for studying chondrogenesis [24,25]. We analyzed the alteration of 
expression of chondrogenic, as well as hypertrophic, markers in these cell lines. Additionally, we 
transfected primary porcine synovium derived mesenchymal stem cells (SDMSCs) [26,27] harboring 
these mutations, which undergo differentiation upon induction with TGF-β in a pellet culture system. 
Here we show that MATN3 mutations, especially SEMD MATN3, significantly inhibit chondrogenesis 
of mesenchymal stem cells and chondroprogenitors. Chondroprogenitors harboring MATN3 mutations 
undergo premature hypertrophy. TGF-β treatment fails to rescue chondrogenesis but instead promotes 
hypertrophy in chondroprogenitors harboring MATN3 mutations.  
2. Results 
2.1. Establishment of Stable ATDC5 Cell Lines Harboring MED and SEMD Associated MATN3 Mutations 
To better understand the function of MATN3 during chondrogenesis, we stably transfected the 
ATDC5 murine chondroprogenitor cell line with a WT MATN3 gene construct or constructs carrying 
the MATN3 point mutations associated with either MED or SEMD, respectively (Figure 1). Several 
cell lines were established by stably transfecting ATDC5 cells with WT, MED or SEMD MATN3 gene 
constructs. The full length WT MATN3 protein that was secreted into the cell media formed primarily 
tetramers along with trimer, dimer and monomer (Figure 2), which is similar to the results previously 
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described in chondrocytes [16,20]. The MED MATN3 protein existed mainly in the form of trimer, 
while the SEMD MATN3 existed in the form of tetramer and trimer (Figure 2).  
Figure 1. Generating multiple epiphyseal dysplasia (MED) and spondyloepimetaphyseal 
dysplasia (SEMD) mutant MATN3 gene constructs. Relative annealing locations of primers 
used to introduce the MED mutation (R116W) into the vWFA domain, and the SEMD 
mutation (C299S) into the first EGF-like domain, of the MATN3 gene. The purpose and 
sequence of each primer used are listed in the table. SP: signal peptide; C–C: coil–coil 
domain; Tags: V5 and 6xHis. 
 
Figure 2. Wild-type (WT) and mutant MATN3 protein production by stably transfected 
ATDC5 cell lines. Western blot analysis using an anti-V5 antibody to detect recombinant 
MATN3 protein in media of stably transfected with WT, MED or the SEMD MATN3 gene.  
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2.2. WT MATN3 Induces Spontaneous Chondrogenesis, while MED and SEMD Mutations Diminish 
MATN3 Induced Chondrogenic Effects, in Chondroprogenitors  
To determine the extent of chondrogenesis in ATDC5 clones expressing WT or mutant MATN3 
genes, total proteoglycan content was measured by alcian blue staining. After culturing in the absence 
of chondrogenesis induction medium for 6 and 12 days, ATDC5 cells exhibited no noticeable alcian 
blue staining (Figure 3A,B). However, positive staining was observed in the cells stably transfected 
with WT MATN3. Cells expressing MED MATN3 exhibited reduced alcian blue staining relative to 
those expressing WT MATN3. Moreover, SEMD MATN3 expressing cells exhibited nearly no alcian 
blue staining on both day 6 and 12 (Figure 3A,B). Real-time RT-PCR analysis demonstrated that WT 
MATN3 enhanced Acan mRNA levels from 7 fold (day 6) to more than 13 fold (day 12) relative to 
parental ATDC5 cells (Figure 4A,B). Furthermore, WT MATN3 expression resulted in a transient up 
regulation in Col2a1 mRNA peaking at day 6 and returning to basal level by day 12 (Figure 4C,D). WT 
MATN3 transfection did not significantly alter Col10a1 mRNA expression in ATDC5 cells  
(Figure 4E,F). In contrast, the MED MATN3 transfected cells exhibited significant suppression of 
Acan mRNA levels relative to WT MATN3 transfected cells, while SEMD MATN3 transfection 
abolished Acan and Col2a1 mRNA levels (Figure 4A–D). However, the hypertrophic marker Col10a1 
was only upregulated significantly in ATDC5 cells expressing the MATN3 mutations at day 6 (Figure 
4E), and remained high at day 12 (Figure 4F). 
Figure 3. MED and SEMD associated point mutations reduce MATN3 induced 
chondrogenesis of ATDC5 chondroprogenitors. (A) Cells were fixed and stained for 
proteoglycan accumulation using alcian blue on day 6 and (B) day 12. Stains were 
extracted with 6 M GuHCl and intensities were quantified. *** p ≤ 0.005 vs. WT MATN3 
stably transfected cells.  
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Figure 4. Chondrogenesis and hypertrophic marker expression in WT and mutant MATN3 
transfected ATDC5 chondroprogenitors. (A,B) Aggrecan mRNA levels; (C,D) collagen II 
mRNA levels; (E,F) collagen X mRNA levels as analyzed by real time RT-PCR in 
untransfected and MATN3 transfected ATDC5 cells on days 6 and 12, respectively.  
* p ≤ 0.05 , ** p ≤ 0.01 vs. WT MATN3 stably transfected ATDC5 cells. 
 
2.3. TGF-β1 Is Incapable of Restoring Normal Chondrogenic Phenotype to Cells Expressing the MED 
or SEMD MATN3 Mutation 
To determine whether TGF-β1 can rescue suppressed chondrogenesis in mutant chondroprogenitors, 
chondrogenic differentiation in response to TGF-β1 treatment was examined by real-time RT-PCR. 
TGF-β1 treatment of ATDC5 cells enhanced Acan mRNA expression by approximately 100 fold  
and Col2a1 by 29 fold on day 6, which remained significantly elevated, with respect to untreated  
ATDC5 controls, at day 12 and day 16 (Figure 5 A(1),B(1)). Even though WT MATN3 can induce 
spontaneous chondrogenesis in chondroprogenitors, TGF-β1 treatment helped to further enhance Acan and 
Col2a1 expression, however, to a lesser extent than observed in the parental ATDC5 control cells  
(Figure 5 A(2),B(2)). In MED MATN3 cells, TGF-β1 treatment increased Acan and Col2a1 at earlier 
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time point (day 6), but was largely ineffective at later time points (Figure 5 A(3),B(3)). In SEMD 
MATN3 cells, neither Acan nor Col2a1 levels were increased in response to TGF-β1 stimulation  
(Figure 5 A(4),B(4)). However, the hypertrophic chondrocyte marker Col10a1 was greatly induced by 
TGF-β1 treatment in both MED and SEMD MATN3 chondroprogenitors, while its levels remained low 
in WT MATN3 cells and the parental ATDC5 cells (Figure 5 C(1–4)). 
Figure 5. Effects of TGF-β1 on the chondrogenic differentiation of ATDC5 cells expressing 
WT, MED or SEMD MATN3 during a 16 day time course. ATDC5 cells were seeded into 12 
well culture plates and the growth media replaced with DMEM:F12 supplemented with or 
without TGF-Β1 (10 ng/mL). On Days 6, 12 and 16, gene expression was quantified in each 
group: untransfected ATDC5; WT MATN3; MED; SEMD, respectively. (A(1–4)) expression 
of Acan; (B(1–4)) Col2a1 and (C(1–4)) Col10a1 was measured using real-time RT-PCR. 
Relative quantities less than 1.00 are so indicated for clarity. * p ≤ 0.05, ** p ≤ 0.01 ,  
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2.4. The Effect of WT and Mutant MATN3 on Chondrogenesis Is Consistent among Different Cell Lines 
We generated multiple stable cell lines harboring each MATN3 transgene (Table 1). The above data 
were obtained from WT3, MED2, and SEMD2. To test whether the effect of WT and mutant MATN3 
on chondroprogenitor cells were consistent among different cell lines, we quantified the basal mRNA 
expression levels of chondrogenesis markers Acan and Col2a1 in two cell lines that expressed lower 
and higher expression level of each MATN3 transgene, respectively. Our results showed that the effect 
of MATN3 on chondrogenesis largely depended on the type of MATN3 expressed (i.e., whether it is 
WT or MED or SEMD), rather than the expression levels of each MATN3 transgene (Figure 6).  




MATN3 Expression Levels 
(Relative to Parental ATDC5) 
WT MATN3 WT1 2.6 
 WT2 18.4 
 WT3 25.7 
MED MATN3 MED1 1.5 
 MED2 1.9 
 MED3 17.2 
SEMD MATN3 SEMD1 6.9 
 SEMD2 46.8 
 SEMD3 1122 
Figure 6. Low and high expression clones of WT and mutant MATN3 transfected cell lines 
show similar trend of chondrogenesis marker expression. (A) Gene expression of aggrecan 
and (B) type II collagen in low and high expression WT or mutant MATN3 stably 
transfected ATDC5 cell lines as analyzed by real time RT-PCR 24 h post seeding.  
* p ≤ 0.05 vs. untransfected ATDC5 cells. 
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2.5. Synovium Derived Mesenchymal Stem Cells Expressing SEMD MATN3 Exhibit Diminished 
Chondrogenesis Potential 
To investigate the effect of WT and mutant MATN3 gene expression in primary stem cells, we 
transfected porcine synovium derived mesenchymal stem cells (SDMSCs) with WT, MED or SEMD 
MATN3 gene construct respectively. They were then incubated in the presence of TGF-β to induce 
chondrogenesis in pellet culture. In comparison to the WT MATN3 expressing SDMSC, the GAG 
content was significantly lower in the SEMD MATN3 expressing SDMSC after 3 and 11 days of 
incubation. The GAG content of the SEMD MATN3 expressing SDMSC or non-transfected SDMSC 
was significantly lower than those transfected with WT MATN3 after 18 days incubation (Figure 7). 
Histological analysis of the SDMSC pellet culture indicates that the size of the pellet of the SEMD 
MATN3 expressing cells was significantly smaller than that of WT MATN3 or MED MATN3 
expressing cells (Figure 8). Furthermore, the chondrogenesis area as indicated by red Safranin-O 
staining in the pellet was significantly smaller in the SEMD MATN3 expressing cells than that of  
WT MATN3 or MED MATN3 expressing cells (Figure 8). This suggests an overall attenuation of 
chondrogenesis in the SDMSCs transfected with the SEMD mutant MATN3 gene. 
Figure 7. SEMD MATN3 transfected primary synovium derived mesenchymal stem cells 
exhibit reduced GAG content. GAG content was measured using a dimethylmethylene blue 
assay and values were normalized to DNA content. Controls are cells transfected with 
empty vector. ** p ≤ 0.01, *** p ≤ 0.005 vs. WT MATN3 transfected cells.  
 
  
Int. J. Mol. Sci. 2014, 15 14565 
 
 
Figure 8. The SEMD MATN3 mutation hinders MATN3 induced chondrogenesis of 
primary porcine synovium derived stem cells. (A–C) Extent of chondrogenesis of WT 
MATN3 transfected; (D–F) MED MATN3 transfected and (G–I) SEMD MATN3 
transfected porcine SDMSC pellets as indicated by Safranin-O staining. Red double headed 
arrows indicate the depth of each pellet’s peripheral cartilaginous zone that stained positive 
with Safranin-O. * Note: A, B and C were reference panels from a previous study [26] for 
the purpose of comparing the extent of chondrogenesis in WT MATN3 transfected cells vs. 
MED or SEMD MATN3 transfected cells. 
 
3. Experimental Section  
The ATDC5 murine chondroprogenitor cell line was acquired from RIKEN cell bank, Japan.  
All cell culture reagents including DMEM:F12, fetal bovine serum, trypsin EDTA solution and Anti 
V5 antibody were purchased from Invitrogen (Carlsbad, CA, USA). Human Transferrin, Selenite, 
Trypan blue, Alcian Blue and GuHCl was purchased from Sigma-Aldrich (St. Louis, MO, USA) while 
TGF-β1 was from Peprotech (Rocky Hill, NJ, USA).  
3.1. Cloning and Construction of MATN3 cDNAs 
The WT MATN3 gene construct and mutant MATN3 construct containing a R116W point mutation 
(MED), were each cloned into expression vectors of pcDNA3.1/V5-His (Invitrogen, Carlsbad, CA, 
USA) as previously described [10,20]. Using similar methods, we also generated MATN3 with the 
C299S point mutation (SEMD) on mouse sequence NM_010770 (Figure 1). Overlapping PCR was 
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performed to create MATN3 cDNA carrying the SEMD mutation using mouse full-length  
pcDNA3.1-MATN3 and Qiagen hotstart Taq (Valencia, CA, USA). Primer sequences are listed in 
Figure 1. The size of the 1.4 kb MATN3 product was confirmed on a 1% agarose gel. The pcDNA 
plasmid plus the mutated MATN3 PCR products were digested with BamH1 and Xba1 (Roche, 
Mannheim, Germany). The SEMD product was then ligated into pcDNA and transformed into 
competent E.coli DH5α cells (Invitrogen, Carlsbad, CA, USA). Colonies grown on ampicillin LB agar 
were picked and expanded. All plasmids were purified using high pure plasmid isolation kit (Roche, 
Mannheim, Germany) to check for the MATN3 inserts using BamH1 and Xba1 digestion. Furthermore, 
individual SEMD and MED clones were sequenced with T7 and BGH primers and confirmed to contain 
the desired nucleotide change in MATN3.  
3.2. Establishing ATDC5 Chondroprogenitor Cell Lines and SDMSCs Harboring MATN3 Mutations 
ATDC5 cells were grown in complete media (DMEM:F12, 5% FBS and 10 µg/mL Transferrin,  
3 × 10−8 M sodium selenite) [24], and maintained at 37 °C and 5% CO2. Cells were split into 12 well 
plates and grown to 95% confluency. Transfection was performed with Lipofectamine 2000 according 
to manufacture instruction (Invitrogen, Carlsbad, CA, USA). Briefly, 1 µg of DNA was mixed with  
2 µL Lipofectamine 2000 in serum free Opti-MEM. Within 20 min at room temperature, the mixture 
was added to cells. After 24 h, media was changed. G418 (5, 6, 7 or 8 µM) was added in the complete 
media to select against cells that were not successfully transfected. Untransfected cells were killed by 
incubation with 4 concentrations of G418 after 4 days. After treatment of 5 µM G4182 for two weeks, 
several individual clones from each transfected cell line were isolated using sterile loops and cultured 
to confluency in new 12 well plates with complete media without G418. All ATDC5 clones containing 
various MATN3 constructs were subcultured for further gene and protein characterization. Several clones 
were analyzed for MATN3 protein production/retention (data not shown). For several lines, gene 
expression analysis was conducted to verify that chondrogenesis marker expression did not greatly 
vary based on relative MATN3 expression alone (Figure 6). After this was confirmed, a single clone 
was selected to represent each WT, MED or SEMD mutant MATN3 line for experiments.  
CD14 negative isolation was used to acquire primary SDMSCs from porcine synovium, as 
previously described [26–28]. SDMSCs were plated at a cell density of 1.8 × 106 cells per 25 cm 
culture flask. After 24 h, cells were stably transfected using 8 µg of the previously described WT, 
MED or SEMD murine MATN3 constructs and 12 µg of FuGENE 6 (Roche, Indianapolis, IN, USA) 
transfection mediator, according to the manufacturer’s instruction.  
3.3. SDS-Polyacrylamide Gel Electrophoresis and Western Blot Analysis 
Stably transfected ATDC5 cells containing the WT or mutant MATN3 genes as well as the 
untransfected ATDC5 control cells were grown in monolayer in 6 well culture plates in complete media. 
After 3 days, cell lysates and supernatants were separately collected for western blot analysis. To 
concentrate MATN3 proteins from media, 50 µL Ni-Agarose beads (Invitrogen, Carlsbad, CA, USA) 
were used to isolate His tagged recombinant MATN3 proteins from 1.0 mL of cell supernatants.  
After 48 h at 4 °C on a shaker, the Ni-agarose beads from all samples were centrifuged and washed  
7 times with buffer containing 20 mM potassium phosphate, 500 mM potassium chloride, 10 mM 
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imidazole pH 7.5. Before protein samples were loaded on to 10% SDS PAGE gel, His tagged proteins 
were dissociated from Ni-Agarose beads by boiling at 95 °C for 10 min in 30 µL 2× SDS gel loading 
buffer, then put on ice and centrifuged to separate Ni-Agarose beads. For western blot, proteins were 
transferred onto Immobilon-PVDF membrane (Millipore Corp., Bedford, MA, USA) in 25 mM Tris, 
192 mM glycine, and 15% methanol. The membranes were blocked in Odyssey® Blocking Buffer for  
1 h and then probed with a mAb against murine V5 (1:5000) (Invitrogen, Carlsbad, CA, USA). 
IRDye® 800CW Conjugated anti-Mouse (diluted 1:10,000) (LI-COR Biosciences, Lincoln, NE, USA) 
was used as secondary antibody. The mutant and WT MATN3 with V5 tag proteins were visualized in 
the 800 nm channel using Odyssey infrared image system according to manufacturer’s instruction  
(LI-COR Biosciences, Lincoln, NE, USA). Molecular protein marker used is specific for the Odyssey 
system and is visualized in the 700 nm channel.  
3.4. Experimental Cell Culture Conditions 
All experiments involving ATDC5 cells were conducted in monolayer cell culture. Each selected 
WT, MED and SEMD MATN3 ATDC5 clone and untransfected ATDC5 control were plated in 
triplicate at 5 × 104 cells/well in 12 well plates in DMEM:F12, 5% FBS and 10 µg/mL Transferrin,  
3 × 10–8 M sodium selenite). Experiments involving primary SDMSCs were conducted using a 
previously described pellet culture system [26]. Transfected and mock-transfected (control) primary 
SDMSCs were detached using trypsin EDTA. 3.0 × 105 cells were centrifuged for 10 min at 500× g  
to obtain cell pellets which were then cultured in 24-well plates for 3, 11 and 18 days in TGF-β1  
(10 ng/mL) supplemented High-Glucose DMEM media containing: proline (40 mg/mL), 100 mM 
dexamethasone, 0.1 mM ascorbic acid 2-phosphate, penicillin (100 U/mL), streptomycin (100 mg/L), 
insulin (6.25 mg/mL), transferring (6.25 mg/mL), selenous acid (6.25 mg/mL), linoleic acid  
(5.35 mg/mL) and BSA (1.25 mg/mL).  
3.5. RNA Isolation and Real-Time RT-PCR  
Three-hundred microliters of Lysis/binding buffer (Ambion, Austin, TX, USA) was added to each 
monolayer cell culture well. All samples were collected and immediately processed to isolate total 
RNA using filter cartridge and buffers from RNAqueous Kit (Ambion, Austin, TX, USA) according to 
manufacturer’s instructions. Total RNA was quantified using a NanoDrop 2000c (Thermo Scientific, 
Wilmington, DE, USA), and 500 ng of RNA was used for cDNA synthesis using iScript Reverse 
Transcription Supermix (Bio-Rad Hercules, CA, USA) for RT-PCR according the manufacturer’s 
instructions. Quantification of mRNA was performed by RT-PCR with QuantiTect SYBR Green PCR 
Kit (Qiagen, Valencia, CA, USA) using the synthesized cDNA and primers described in Table 2 via 
Bio-Rad 96 well thermo cycler. Ribosomal RNA 18S was used as the internal control. The cycle 
threshold (Ct) values for specific target gene and 18S of each cDNA test sample (test) and control (ctl) 
were measured and obtained using Opticon Monitor Analysis Software: Version 2.02 (Bio-Rad, 
Hercules, CA, USA). In accordance with the delta delta Ct (∆∆Ct) method, relative transcript levels 
were calculated as x = 2(−ΔΔCt), where ΔΔCt = ΔE − ΔC, ΔE = Cttest − Ct18S; ΔC = Ctctl − Ct18S. 
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Table 2. Forward and reverse primer sequences used in gene expression analysis. 
Gene Forward Reverse 
Acan CAGTGCGATGCAGGCTGGCT CCTCCGGCACTCGTTGGCTG 
Col2a1 CACACTGGTAAGTGGGGCAAGACCG GGATTGTGTTGTTTCAGGGTTCGGG
Col10a1 GCCAGGAAAGCTGCCCCACG GAGGTCCGGTTGGGCCTGGT 
MATN3 TTCCACCCGCGCGCCATATTC CGTGTCTGTGGCCCCGATGTC 
3.6. Alcian Blue Staining and Quantification 
On Days 6 and 12, media was removed from each of the stable transfected ATDC5 clones and 
gently washed with sterile 1× PBS to remove detached/dead cells. Cells were fixed in cold 100% 
methanol for 2 min at −20 °C and gently washed with 1× PBS. Samples were stained overnight with 
500 µL of 0.1% Alcian blue in 0.1 M HCl pH = 1.0, plates were washed 3 times in milli-Q water 
(Millipore, Billerica, MA, USA). Images of Alcian Blue staining were acquired using a Leica MZ6 
Stereo microscope (Leica Microsystems, Buffalo Grove, IL, USA). Blue stains were extracted for 
quantification using 300 µL of 6 M GuHCl, which was incubated overnight. Extracted color was 
measured in a 96 well plate at 620 nm using a spectrophotometer.  
3.7. Histology and Safranin-O Staining of Primary SDMSC Cell Pellets 
Primary SDMSC cell pellets were fixed using 4% paraformaldehyde in PBS (pH 7.4) for 24 h at  
4 °C followed by dehydration in ethanol. Specimens were then cleared using xylene and embedded in 
paraffin. Individual sections (5 µm) were then cut and subsequently stained with safranin-O/fast green 
(for visualization of GAG) and counterstained with hematoxylin [26].  
3.8. GAG Quantification with Dimethylmethylene Blue Assay 
After 3, 11 and 18 days in culture, primary SDMSC cell pellets were digested in buffer containing 
papain (125 mg/mL), 100 mM phosphate, 10 mM EDTA and 10 mM cysteine. Using the digested 
lysates, a dimethylmethylene blue assay [29] was conducted to measure GAG content with a 
spectrophotometer (PerkinElmer, Norwalk, CT, USA). Bovine chondrotin sulfate was used to generate 
the standard curve utilized for GAG quantification. DNA content, as measured by Hoechst 33258 dye 
and a spectrofluorometer (QM-1; Photon Technology International, South Brunswick, NJ, USA), was 
used to control for cell number. Type I calf thymus DNA (Sigma, St. Louis, MO, USA) was used to 
generate the standard curve utilized for DNA quantification.  
3.9. Statistical Analysis 
All quantitative data are expressed as mean ± SDM (standard deviation of the mean). Statistics were 
conducted using one-way ANOVA followed by post-hoc analysis. In Figure 5, a Student’s t-test was 
used to compare TGF-β1 treated and untreated groups. Differences between groups were considered 
statistically significant when p-value ≤0.05. 
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4. Discussion  
Extracellular matrix (ECM) proteins have been proposed to provide a microenvironment suitable 
for maintaining the chondrogenic phenotype of differentiating mesenchymal stem cells [26], which is 
required for proper musculoskeletal development. However, it is not clear whether mutations of an ECM 
gene can affect chondroprogenitor cell differentiation into chondrocytes. Several chondrodysplasia 
mutations including MED and SEMD have been mapped to MATN3, a gene encoding a non-collagenous 
matrix glycoprotein [2,13,14,16,17,20,30]. Previous studies have utilized transient transfection of the 
MED (R116W) and SEMD (C299S) mutant MATN3 gene constructs into chondrocytes to understand 
their effects [16,20]. Until now, it has been generally assumed that the molecular defects of MED and 
SEMD reside in chondrocytes, which were thought to be the only type of cells within cartilage. 
However, in recent years, it has been shown that cartilage contains a population of progenitor cells of 
the mesenchymal origin that can differentiate along the chondrogenic lineage, which is vital for 
cartilage development [31,32]. 
The main goal of our study was to understand the role of the WT MATN3 gene, as well as MED and 
SEMD mutant MATN3 genes, during the process of chondroprogenitor cell differentiation, which is a 
crucial preamble to articular cartilage tissue formation and endochondral ossification during skeletal 
development. To do this, we established several chondroprogenitor cell lines by stably transfecting 
ATDC5 cells with the wild type, MED or SEMD MATN3 gene constructs. Using these lines, we 
demonstrated that chondroprogenitors expressing the WT MATN3 gene show signs of spontaneous 
chondrogenic differentiation. Relative to the WT MATN3 transfected cells, ATDC5 cells carrying the 
MED MATN3 mutation exhibited reduced chondrogenic marker expression at most tested time  
points. This diminishment was even more pronounced in cells carrying the SEMD MATN3 mutation. 
Consistent with mRNA analysis of chondrogenesis markers, alcian blue staining intensities indicated a 
reduction of proteoglycan accumulation in ATDC5 cells carrying either the MED or SEMD MATN3 
mutant construct. The SEMD MATN3 group exhibited the greatest reduction in alcian blue staining 
intensity relative to wild-type MATN3 expressing cells. Similarly, primary SDMSCs expressing the 
SEMD MATN3 mutant construct exhibited a significant reduction of GAG content compared to the 
WT MATN3 group. In particular, our experiments with SDMSCs demonstrated that the presence of the 
SEMD associated mutant MATN3 gene can hinder the process of chondrogenesis in primary cells, in a 
similar way to that observed in the ATDC5 cell line, confirming that this phenomenon is not simply an 
isolated event observed in one particular cell model, but rather a definitive abnormality observed in 
cells that express this MATN3 mutation.  
Furthermore, both the MED MATN3 and SEMD MATN3 expressing ATDC5 cells exhibit elevated 
type X collagen mRNA levels relative to the control cell group whereas WT MATN3 cells remain at 
normal levels, strongly suggesting that the MED and SEMD associated MATN3 mutations induce 
premature hypertrophy during chondroprogenitor cell differentiation. Taken together, these findings 
suggested that the MED and SEMD associated MATN3 mutation can dramatically impact the early 
stages of chondrogenesis in both chondroprogenitor cells by abrogating proteoglycan accumulation. This 
is the first study to report the evidence suggesting that the MED and SEMD mutations, and the SEMD 
mutation in particular, affect early chondrogenesis of progenitor cells. Chondrogenesis, as part of  
the endochondral ossification process, is a crucial step that can influence skeletal formation [33,34]. 
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Interestingly, the significant elevation of the hypertrophic markers observed in the MED and SEMD 
MATN3 expressing cells also suggest that these MATN3 mutations may promote premature hypertrophy. 
Because the coordination between the proliferative and hypertrophic stage of chondrogenesis is critical to 
the longitudinal bone growth during skeletal development [35], the occurrence of premature hypertrophy 
may shorten the chondrogenic process thereby negatively impacting bone growth [36].  
Previous studies have demonstrated that TGF-β1 treatment can promote chondrogenesis while also 
preventing chondrocyte hypertrophy [37,38]. To determine whether TGF-β1 can remedy the reduced 
chondrogenic potential and increased hypertrophy that is typical of mutant MATN3 expressing 
progenitor lines, we treated these cells with TGF-β1 for up to 16 days in culture. TGF-β1 treatment 
appeared to enhance aggrecan expression in normal chondroprogenitor cells as well as WT-MATN3 
transfected cells but failed to elevate its expression in the cells harboring either MED or SEMD 
MATN3 mutations. The inability of TGF-β1 to rescue the attenuation of the chondrogenic marker 
aggrecan in the MED and SEMD expressing cells suggests that TGF-β1 is not effective in restoring the 
normal chondrogenic phenotype in mutant chondroprogenitor cells. What is more, TGF-β1 treatment 
further increased the already elevated type X collagen mRNA levels in both MED and SEMD MATN3 
expressing cells. This suggests that the combined effect of TGF-β1 and mutant MATN3 proteins may 
expedite terminal differentiation in these chondroprogenitor cells. 
Overall, the present study presents evidence supporting the hypothesis that cartilage ECM protein 
MATN3 provides a microenvironment suitable for promoting chondrogenic differentiation and 
inhibiting hypertrophy for chondroprogenitors. We demonstrate here for the first time that MED or 
SEMD chondrodysplasia associated MATN3 missense mutations have a dominant effect to render 
attenuated chondrogenesis and premature hypertrophy in chondroprogenitor cells.  
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